ReNeuron Group (LSE:RENE) Dividend Payout Ratio : 0.00 (As of Sep. 2023)

View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group Dividend Payout Ratio?

ReNeuron Group's dividend payout ratio for the months ended in Sep. 2023 was 0.00.

The historical rank and industry rank for ReNeuron Group's Dividend Payout Ratio or its related term are showing as below:

LSE:RENE's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-27), the Dividend Yield % of ReNeuron Group is 0.00%.

ReNeuron Group's Dividends per Share for the months ended in Sep. 2023 was £0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

ReNeuron Group Dividend Payout Ratio Historical Data

The historical data trend for ReNeuron Group's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Dividend Payout Ratio Chart

ReNeuron Group Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Dividend Payout Ratio

Get a 7-Day Free Trial

ReNeuron Group Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ReNeuron Group's Dividend Payout Ratio

For the Biotechnology subindustry, ReNeuron Group's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ReNeuron Group's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Dividend Payout Ratio falls into.

ReNeuron Group Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

ReNeuron Group's Dividend Payout Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Mar. 2023 )	/	EPS without NRI (A: Mar. 2023 )
	=	0	/	-0.095
	=	N/A

ReNeuron Group's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.05
	=	N/A

ReNeuron Group (LSE:RENE) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

ReNeuron Group Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (LSE:RENE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

RNUGF:USA RENE.GB:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.